Compare Globus Medical Inc. Class A Common Stock (GMED) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Global X SuperDividend ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $77.65 (market cap $10.25B), while Global X SuperDividend ETF trades at $23.66 (market cap $1.18B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 8.7× Global X SuperDividend ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Global X SuperDividend ETF for 49 Days on average.
| GMED | SDIV | |
|---|---|---|
Market Cap | $10.25B | $1.18B |
Volume | 1,059,528 | 500,093 |
Sector | Health | Broad Market / Factor |
52-Week High | $96.82 | $26.34 |
52-Week Low | $58.33 | $23.16 |
Typical Hold Time | 0 Days | 49 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SDIV trades at $23.88, down 0.21% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, with a 66% price decline since inception noted by Seeking Alpha on September 11, 2026. Recent institutional buying includes Ameritas Advisory increasing its position by 92.6% in Q2 2026 per SEC filings.
High dividend yield attracts income investors but comes with significant capital depreciation risks. Media coverage highlights sustainability concerns, while technical indicators suggest near-term consolidation. The outlook remains cautious due to persistent underperformance versus benchmarks and high volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
